Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

The New England journal of medicine - 9 Oct 2014

Wagle Nikhil, Grabiner Brian C, Van Allen Eliezer M, Amin-Mansour Ali, Taylor-Weiner Amaro, Rosenberg Mara, Gray Nathanael, Barletta Justine A, Guo Yanan, Swanson Scott J, Ruan Daniel T, Hanna Glenn J, Haddad Robert I, Getz Gad, Kwiatkowski David J, Carter Scott L, Sabatini David M, Jänne Pasi A, Garraway Levi A, Lorch Jochen H

Abstract excerpt

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordinary 18-month response. Whole-exome sequencing of pretreatment and drug-resistant tumors revealed a nonsense mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphatic Metastasis
Share to Radiography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sirolimus

Share to Combined Modality Therapy

Share to Everolimus

Share to Thyroid Carcinoma, Anaplastic

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis Complex 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 25295501
DOI: 10.1056/NEJMoa1403352
PMCID: PMC4564868

Genes

MTOR
TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response and acquired resistance to everolimus in anaplastic thyroid cancer.PMID 25295501Read ↗

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Semantic proximity Read ↗

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.Semantic proximity Read ↗

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.Semantic proximity Read ↗

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.Semantic proximity Read ↗

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.Semantic proximity Read ↗

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.Semantic proximity Read ↗

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Semantic proximity Read ↗

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.